• 1
    Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med. 1993; 328: 10231030.
  • 2
    The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329: 987994.
  • 3
    Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has “high-risk” disease? Blood. 1994; 83: 11651173.
  • 4
    Laport GF, Williams SF. The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Semin Oncol. 1998; 25: 502517.
  • 5
    Salles G, Coiffier B. Autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Baillieres Best Pract Res Clin Haematol. 1999; 12: 151169.
  • 6
    Pettengell R, Radford JA, Mogenstern GR, et al. Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma. J Clin Oncol. 1996; 14: 586592.
  • 7
    Haioun C, Lepage E, Gisselbrecht C, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997; 15: 11311137.
  • 8
    Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med. 1997; 336: 12901297.
  • 9
    Cortelazzo S, Rossi A, Viero P, et al. BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma. Br J Haematol. 1997; 99: 379385.
  • 10
    Vitolo U, Cortellazzo S, Liberati AM, et al. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma. J Clin Oncol. 1997; 15: 491498.
  • 11
    Santini G, Salvagno L, Leoni P, et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol. 1998; 16: 27962802.
  • 12
    Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol—a Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol. 2000; 18: 30253030.
  • 13
    Reyes F, Lepage E, Morel P, et al. Failure of first line inductive high-dose chemotherapy in poor prognosis patients with aggressive lymphoma: updated results of the randomized LNH93-3 study [abstract 2640]. Blood. 1997; 90 (Suppl 2): S594.
  • 14
    Kaiser U, Uebelacker I, Birkmann J, et al. High dose therapy with autologous stem cell transplantation in aggressive NHL: results of a randomized multicenter study [abstract 2716]. Blood. 1999; 94 (Suppl 1): S611.
  • 15
    Shipp MA, Abeloff MD, Antman KH, et al. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol. 1999; 17: 423429.
  • 16
    Bosly A, Sonnet A, Salles G, et al. Superiority of late over early intensification in relapsing/refractory aggressive non-Hodgkin's lymphoma: a randomized study from the GELA: LNH RP 93 [abstract 2639]. Blood. 1997; 90 (Suppl 1): S594.
  • 17
    Gianni AM, Bregni M, Siena S, et al. Rapid and complete hemopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high dose chemo-radiotherapy? Hematol Oncol. 1989; 7: 139148.
  • 18
    Tarella C, Gavarotti P, Caracciolo D, et al. Haematological support of high-dose sequential chemotherapy: clinical evidence for reduction of toxicity and high response rates in poor risk lymphomas. Ann Oncol. 1995; 6 (Suppl 4): S3S8.
  • 19
    Tarella C, Di Nicola M, Caracciolo D, et al. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at high risk for low mobilization. Bone Marrow Transplant. 2002; 30: 725732.
  • 20
    Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84: 13611392.
  • 21
    Jaffe ES. Classification of natural killer (NK) cell and NK-like T-cell malignancies. Blood. 1996; 87: 12071210.
  • 22
    Weinstein HJ, Cassady JR, Levey R. Long term results of the APO protocol (vincristine, doxorubicin, and prednisone) for treatment of mediastinal lymphoblastic lymphoma. J Clin Oncol. 1983; 1: 537541.
  • 23
    Tarella C, Zallio F, Caracciolo D, et al. High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity. Leukemia. 2001; 15: 256263.
  • 24
    Tarella C, Ferrero D, Bregni M, et al. Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSF. Eur J Cancer. 1991; 27: 2227.
  • 25
    Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17: 12441253.
  • 26
    Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 27
    Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc. 1972; 135: 185206.
  • 28
    Cox DR. Regression models and life tables. J R Stat Soc Ser B. 1972; 34: 187220.
  • 29
    Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet. 1996; 347: 353357.
  • 30
    Hartmann O, Le Corroller AG, Blaise D, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphoma: hematologic recovery and cost. Ann Intern Med. 1997; 126: 600607.
  • 31
    Shipp MA, Harrington DP, Klatt MM, et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med. 1986; 104: 757765.
  • 32
    Coiffier B, Gisselbrecht C, Vose JM, et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol. 1991; 9: 211219.
  • 33
    Vitolo U, Bertini M, Brusamolino E, et al. MACOP-B treatment in diffuse large cell lymphoma: identification of prognostic groups in an Italian multicentric study. J Clin Oncol. 1992; 10: 219227.
  • 34
    Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol. 1986; 4: 14701480.
  • 35
    Coiffier B, Brousse N, Peuchmaur M, et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Ann Oncol. 1990; 1: 4550.
  • 36
    Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood. 1998; 92: 7682.
  • 37
    Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphoma: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998; 16: 27802795.
  • 38
    Wilder RB, Rodriguez MA, Medeiros LJ, et al. International Prognostic Index-based outcomes for diffuse large B-cell lymphomas. Cancer. 2002; 94: 30833088.
  • 39
    Blay JY, Gomez F, Sebban C, et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Blood. 1998; 92: 35623568.
  • 40
    Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403: 503511.
  • 41
    Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002; 8: 6874.
  • 42
    Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 235242.
  • 43
    Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2001; 19: 389397.
  • 44
    Voso MT, Pantel G, Weis M, et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol. 2000; 109: 729735.
  • 45
    Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood. 2000; 96: 864869.
  • 46
    Flinn IW, O'Donnell PV, Goodrich A, et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2000; 6: 628632.
  • 47
    Ladetto M, Zallio F, Vallet S, et al. Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. Leukemia. 2001; 15: 19411949.